FDA Approves Relugolix for Advanced Prostate Cancer
Jan 26, 2021 · Known as androgen deprivation therapy (ADT), these treatments are akin to putting a stopper in a car’s gas tank: robbing prostate tumors of the fuel they need to grow and spread.
Long-Term, High-Dose Radiation, ADT Boosts Survival in
Jan 30, 2024 · Higher doses of radiation, combined with long-term androgen deprivation therapy (ADT), improved long-term survival in patients with high-risk prostate cancer without significant impacts on their quality of life.
Study helps predict how long it will take for testosterone to return …
Sep 25, 2024 · A study led by researchers from the UCLA Health Jonsson Comprehensive Cancer Center sheds light on testosterone recovery following androgen deprivation therapy (ADT) in men undergoing...
New ‘take at home’ prostate cancer pill approved by NICE
Jul 19, 2024 · Relugolix, a type of androgen deprivation therapy, is recommended by NICE for people with hormone sensitive prostate cancer. It lowers testosterone levels and reduces the risk of cardiovascular events compared with injections.
Improved Outcomes with Enzalutamide in Biochemically Recurrent …
Oct 18, 2023 · Patients with prostate cancer who have high-risk biochemical recurrence have an increased risk of progression. The efficacy and safety of enzalutamide plus androgen-deprivation therapy and...
Attacking metastatic prostate cancer early with combination …
Mar 18, 2024 · The UCLA team conducted a single-arm phase 2 trial to evaluate whether the addition of metastasis-directed SBRT and dual androgen receptor pathway inhibitors, a more potent but shorter course of hormonal therapy, to intermittent androgen deprivation therapy improves the recurrence rates for men.
Key Findings From ARANOTE: Darolutamide Plus ADT in mHSPC
5 days ago · The panelist discusses how the ARANOTE trial demonstrated significant benefits of adding darolutamide to androgen deprivation therapy for patients with metastatic hormone-sensitive prostate cancer, showing improvements in radiographic progression-free survival and other key outcomes.
Darolutamide Extends Survival in Metastatic Prostate Cancer
Mar 25, 2022 · Darolutamide (Nubeqa) is a pill that blocks androgens from binding to cancer cells and extends survival in men with hormone-sensitive prostate cancer that has spread. Learn about the results of a large clinical trial that compared darolutamide with …
Phase 2 data for ERLEADA® (apalutamide) plus androgen deprivation ...
SAN ANTONIO, May 3, 2024 – Johnson & Johnson announced today results from the open-label, single-arm Phase 2 Apa-RP study evaluating adjuvant treatment with ERLEADA ® (apalutamide) and androgen deprivation therapy (ADT) in patients with HRLPC who have undergone radical prostatectomy (RP).
Androgen deprivation therapy use and duration with definitive ...
Jan 17, 2022 · Several randomised trials have investigated the oncological benefit of adding androgen deprivation therapy (ADT) to definitive radiotherapy for prostate cancer, as well as the benefit of prolonging ADT duration.